FY2025 4Q Financial Results Presentation Summary of Q&A Session

Notice of Convocation of the 167th Ordinary General Meeting of Shareholders Other Matters Subject to the Electronic Provision

Notice of Convocation of the 167th Ordinary General Meeting of Shareholders

FY2025 Financial Results Presentation Materials with Script

Notice Concerning Recording of Extraordinary Income and Losses (Consolidated and Non-consolidated)

Results Presentation of FY2025

FY2025 Summary of Consolidated Financial Statements

Notice Regarding Results of Tender Offer for Share Certificates, Etc. of KAINOS Laboratories, Inc. (Securities Code: 4556)

Announcement of Extraordinary Gains (Gain on Sale of Investment Securities)

Summary of Q&A Session for Management Presentation on Feb 27 2026

Notice Concerning Change in Equity-Method Affiliate (Becoming a Consolidated Subsidiary)

Presentation Materials for Management Presentation on Feb 27 2026 with Script

(Amendment) Notice Regarding Amendment to “Notice Regarding Commencement of Tender Offer for Share Certificates, Etc. of KAINOS Laboratories, Inc. (Securities Code: 4556)” and Public Notice of Commencementof Tender Offer Dueto Filingof Amendment Statement

Notice of Formulation of Management Plan “Mission 2030” Phase 2 (FY2026–FY2028)

Presentation Material for Management Presentation on Feb 27th 2026

Notice of Commencement of Consideration of Spin-off of Styrene-Related Businesses

FY2025 Third Quarter Financial Results Presentation Summary of Q&A Session

FY2025 Third Quarter Financial Results Presentation Materials with Script

Notice Regarding Commencement of Tender Offer for Share Certificates, Etc. of KAINOS Laboratories, Inc. (Securities Code: 4556)

Notice Regarding Recognition of Extraordinary Losses

Notice Regarding Personnel Changes in Executive Officers

FY2025 Third Quarter Financial Results Presentation Materials

FY2025 Third Quarter Summary of Consolidated Financial Results